Literature DB >> 20619252

Hemoglobin adducts in 1,3-butadiene exposed Czech workers: female-male comparisons.

Pamela M Vacek1, Richard J Albertini, Radim J Sram, Patricia Upton, James A Swenberg.   

Abstract

We previously reported results of a molecular epidemiological study of female and male 1,3-butadiene (BD) exposed Czech workers showing that females appeared to absorb or metabolize less BD per unit exposure concentration than did males, based on metabolite concentrations in urine (Chem. Biol. Interact. 166 (2007) 63-77). However, that unexpected observation could not be verified at the time because the only additional BD metabolite measurement attempted was for 1,2,3,4-diepoxybutane (DEB) as reflected in specific N,N[2,3-dihydroxy-1,4-butyl]valine (pyr-Val) hemoglobin adduct concentrations, which were not quantifiable in any subject with the method then employed. Neither somatic gene mutations nor chromosome aberrations were associated with BD exposure levels in that study, consistent with findings in an earlier Czech study of males only. We have since measured production and accumulation of the 1,2-dihydroxy-3,4-epoxybutane (EBD) metabolite as reflected in N-[2,3,4-trihydroxy-butyl]valine (THB-Val) hemoglobin adduct concentrations. The mean THB-Val concentration was significantly higher in exposed males than in control males (922.3pmol/g and 275.5pmol/g, respectively), but exposed and control females did not differ significantly (224.5pmol/g and 181.1pmol/g, respectively). In both the control and exposed groups mean THB-Val concentrations were significantly higher for males than females. THB-Val concentrations were significantly correlated with mean 8-h TWA exposures for both males and females, but the rate of increase with increasing BD exposure was significantly lower for females. THB-Val concentrations also increased with increasing urine M2 metabolite [isomeric mixture of 1-hydroxy-2-{N-actylcysteinyl}-3-butene and 2-hydroxy-1-{N-acetylcysteinyl}-3-butene] concentrations in both sexes but the rate of increase was also lower in females than in males. There were no significant correlations between THB-Val concentrations and either somatic gene mutations or chromosome aberrations in either males or females. These results using another biomarker to measure a second metabolite of BD support the original conclusion that females absorb or metabolize less BD than males per unit exposure and indicate that the size of the difference increases with exposure. This observation in humans differs from findings in rodents where at prolonged exposures to high BD levels the females form higher amounts of hemoglobin adducts than do males, a difference that disappears at shorter duration lower exposure levels, while female susceptibility to BD induced mutations and tumorgenesis in rodents appears to persist at all BD exposure levels.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20619252     DOI: 10.1016/j.cbi.2010.06.017

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  9 in total

1.  Formation of 1,2:3,4-diepoxybutane-specific hemoglobin adducts in 1,3-butadiene exposed workers.

Authors:  Gunnar Boysen; Nadia I Georgieva; Narisa K Bordeerat; Radim J Sram; Pamela Vacek; Richard J Albertini; James A Swenberg
Journal:  Toxicol Sci       Date:  2011-10-14       Impact factor: 4.849

2.  1,3-Butadiene: Biomarkers and application to risk assessment.

Authors:  James A Swenberg; Narisa K Bordeerat; Gunnar Boysen; Sujey Carro; Nadia I Georgieva; Jun Nakamura; John M Troutman; Patricia B Upton; Richard J Albertini; Pamela M Vacek; Vernon E Walker; Radim J Sram; Melissa Goggin; Natalia Tretyakova
Journal:  Chem Biol Interact       Date:  2010-10-23       Impact factor: 5.192

Review 3.  Mercapturic acids: recent advances in their determination by liquid chromatography/mass spectrometry and their use in toxicant metabolism studies and in occupational and environmental exposure studies.

Authors:  Patricia I Mathias; Clayton B'hymer
Journal:  Biomarkers       Date:  2016-02-22       Impact factor: 2.658

4.  NanoLC/ESI+ HRMS3 quantitation of DNA adducts induced by 1,3-butadiene.

Authors:  Dewakar Sangaraju; Peter W Villalta; Susith Wickramaratne; James Swenberg; Natalia Tretyakova
Journal:  J Am Soc Mass Spectrom       Date:  2014-05-28       Impact factor: 3.109

5.  Quantitative analysis of trihydroxybutyl mercapturic acid, a urinary metabolite of 1,3-butadiene, in humans.

Authors:  Srikanth Kotapati; Brock A Matter; Amy L Grant; Natalia Y Tretyakova
Journal:  Chem Res Toxicol       Date:  2011-08-04       Impact factor: 3.739

6.  NanoHPLC-nanoESI(+)-MS/MS quantitation of bis-N7-guanine DNA-DNA cross-links in tissues of B6C3F1 mice exposed to subppm levels of 1,3-butadiene.

Authors:  Dewakar Sangaraju; Melissa Goggin; Vernon Walker; James Swenberg; Natalia Tretyakova
Journal:  Anal Chem       Date:  2012-01-26       Impact factor: 6.986

7.  Quantitative cancer risk assessment and local mortality burden for ambient air pollution in an eastern Mediterranean City.

Authors:  Hassan R Dhaini; Thérèse Salameh; Antoine Waked; Stéphane Sauvage; Agnès Borbon; Paola Formenti; Jean-François Doussin; Nadine Locoge; Charbel Afif
Journal:  Environ Sci Pollut Res Int       Date:  2017-04-18       Impact factor: 4.223

8.  Capillary HPLC-accurate mass MS/MS quantitation of N7-(2,3,4-trihydroxybut-1-yl)-guanine adducts of 1,3-butadiene in human leukocyte DNA.

Authors:  Dewakar Sangaraju; Peter Villalta; Melissa Goggin; Maria O Agunsoye; Colin Campbell; Natalia Tretyakova
Journal:  Chem Res Toxicol       Date:  2013-09-12       Impact factor: 3.739

9.  Bis-butanediol-mercapturic acid (bis-BDMA) as a urinary biomarker of metabolic activation of butadiene to its ultimate carcinogenic species.

Authors:  Srikanth Kotapati; Dewakar Sangaraju; Amanda Esades; Lance Hallberg; Vernon E Walker; James A Swenberg; Natalia Y Tretyakova
Journal:  Carcinogenesis       Date:  2014-02-14       Impact factor: 4.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.